| Abstrakt: |
A solution of L-cysteine for use in total parenteral nutrition (TPN) comprising, about 50 mg/mL of L-cysteine hydrochloride monohydrate, or equivalent amount of a pharmaceutically acceptable L-cysteine or a salt or hydrate thereof, in a pharmaceutically acceptable carrier; wherein: after 12 months of storage in a sealed single-use vial at room temperature: the total amount of oxygen within the sealed vial is no more than about 5% and the solution: contains no more than 150 ppb aluminum, is substantially free of visually detectable particulate matter, and has a pH from 1.0 to 2.5. Keywords: Acute-Phase Proteins; Aluminum; Amino Acids; Beta-Globulins; Blood Proteins; Business; Carrier Proteins; Chalcogens; Cysteine; Diet and Nutrition; Exela Pharma Sciences LLC; Feeding Methods; Health and Medicine; Iron-Binding Proteins; Light Metals; Neutral Amino Acids; Nutrition Therapy; Nutritional Support; Parenteral Nutrition; Peptides; Proteins; Sulfhydryl Compounds; Sulfur Amino Acids; Total Parenteral Nutrition; Transferrin EN Acute-Phase Proteins Aluminum Amino Acids Beta-Globulins Blood Proteins Business Carrier Proteins Chalcogens Cysteine Diet and Nutrition Exela Pharma Sciences LLC Feeding Methods Health and Medicine Iron-Binding Proteins Light Metals Neutral Amino Acids Nutrition Therapy Nutritional Support Parenteral Nutrition Peptides Proteins Sulfhydryl Compounds Sulfur Amino Acids Total Parenteral Nutrition Transferrin 10315 10315 1 07/17/23 20230721 NES 230721 2023 JUL 21 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- A patent by the inventors Koganti, Aruna (Lenoir, NC, US), Koneru, Phanesh (Waxhaw, NC, US), Maloney, John (Salisbury, NC, US), filed on September 22, 2022, was published online on June 27, 2023, according to news reporting originating from Alexandria, Virginia, by NewsRx correspondents. [Extracted from the article] |
